TNFRSF8 and lymphoproliferative syndrome: Further, we identified a novel recurrent NPM::TYK2 gene fusion in a proportion of primary cutaneous CD30+ lymphoproliferative disorders (15%), which activates STAT1/3/5 signaling and promotes cell proliferation (164).